A phase I study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor targeted therapies

PURPOSE: The PI3K/Akt/mTOR pathway is dysregulated in metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. The primary aim of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of buparlisib a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: McKay, Rana R., De Velasco, Guillermo, Werner, Lillian, Bellmunt, Joaquim, Harshman, Lauren, Sweeney, Christopher, Rosenberg, Jonathan E., Hirsch, Michelle, Signoretti, Sabina, Van Allen, Eliezer, Walsh, Meghara, Vaishampayan, Ulka, McDermott, David F., Choueiri, Toni K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567751/
https://ncbi.nlm.nih.gov/pubmed/27198170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30056
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky